Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).

Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).
复制标题

DOI:
10.1093/annonc/mdy117
复制
发表时间:
2018-06-01
期刊:
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子:
--
通讯作者:
German Society of Hematology and Medical Oncology Infectious Diseases Working Group (AGIHO)
German Society of Hematology and Medical Oncology Infectious Diseases Working Group (AGIHO)
中科院分区:
其他
文献类型:
--
作者:
Rieger CT;Liss B;Mellinghoff S;Buchheidt D;Cornely OA;Egerer G;Heinz WJ;Hentrich M;Maschmeyer G;Mayer K;Sandherr M;Silling G;Ullmann A;Vehreschild MJGT;von Lilienfeld-Toal M;Wolf HH;Lehners N;German Society of Hematology and Medical Oncology Infectious Diseases Working Group (AGIHO)

文献摘要

参考文献

被引文献

相似文献

感染性并发症是恶性肿瘤患者发病和死亡的重要原因,特别是在接受抗癌治疗时。通过疫苗预防感染是癌症患者临床护理的一个重要方面。在制定疫苗接种策略时,需要考虑潜在疾病以及免疫疗法的免疫影响。本指南提供了关于癌症患者(包括自体干细胞移植受者)使用疫苗的临床建议,而同种异体干细胞移植则是另一项指南的主题。该文件由德国血液学和肿瘤医学学会(DGHO)传染病工作组(AGIHO)通过审查现有数据并应用循证医学标准编写。
Infectious complications are a significant cause of morbidity and mortality in patients with malignancies specifically when receiving anticancer treatments. Prevention of infection through vaccines is an important aspect of clinical care of cancer patients. Immunocompromising effects of the underlying disease as well as of antineoplastic therapies need to be considered when devising vaccination strategies. This guideline provides clinical recommendations on vaccine use in cancer patients including autologous stem cell transplant recipients, while allogeneic stem cell transplantation is subject of a separate guideline. The document was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) by reviewing currently available data and applying evidence-based medicine criteria.
DOI: 10.1016/j.vaccine.2010.01.025
发表时间: 2010-03-24
期刊: VACCINE
影响因子: 5.5
作者:
Cordonnier, Catherine;Labopin, Myriam;Ljungman, Per
通讯作者: Ljungman, Per
DOI: 10.1128/iai.72.1.332-337.2004
发表时间: 2004-01-01
影响因子: 3.1
作者:
Balmer, P;Falconer, M;Borrow, R
通讯作者: Borrow, R
DOI: 10.1016/j.medmal.2008.06.031
发表时间: 2008-10-01
影响因子: 5
作者:
Bruyand, M.;Receveur, M. -C.;Malvy, D.
通讯作者: Malvy, D.
DOI: 10.1002/cncr.21203
发表时间: 2005-08-01
期刊: CANCER
影响因子: 6.2
作者:
Cooksley, CD;Avritscher, EBC;Elting, LS
通讯作者: Elting, LS
DOI: 10.1016/j.bbmt.2015.12.025
发表时间: 2016-04-01
影响因子: 4.3
作者:
Aoki, Takahiro;Koh, Katsuyoshi;Hanada, Ryoji
通讯作者: Hanada, Ryoji